Summit Hotel Properties, Inc. INN

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that, further to its press release of September 9, 2026, it has complete a private placement of 247,314 units of the Company (the "Units") at a price of C$1.87 per Unit for gross proceeds of C$462,477 (the "Offering").

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a private placement of up to 535,000 units of the Company (the "Units") at a price of C$1.87 per Unit for gross proceeds up to C$1,000,000 (the "Offering"). The Offering is expected to close on or around September 17, 2026.

On August 5, Summit Hotel Properties (NYSE:INN) reported second-quarter 2026 results that flipped last year’s loss into a $3.9 million profit, or $0.04 per diluted share, versus a $1.6 million loss a year earlier. Operating income jumped 27.3% to $28.9 million, powered by average daily rates that climbed 7.1% to $178.42. For a hotel REIT […]

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), today reported today 2026 financial consolidated results for the six and three months ended June 30, 2026.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Moby summary of Summit Hotel Properties, Inc.'s Q2 2026 earnings call

Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), today announced results for the three and six months ended June 30, 2026.

Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), through B.I. Sky Global Ltd., the consumer wellness subsidiary of Innocan, is proud to announce that its flagship skincare brand, Valitic, has received more than 100,000 positive verified customer reviews across leading US online marketplaces.